Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas

Journal of Clinical Oncology

Volumn 24, Issue 2, 2006, Pages 274-287

  Bredel, Markus ^a   Bredel, Claudia ^a   Juric, Dejan ^a   Duran, George E ^a   Yu, Ron X ^a   Harsh, Griffith R ^a   Vogel, Hannes ^a   Recht, Lawrence D ^a   Scheck, Adrienne C ^a   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPSIN II; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; CARMUSTINE; DACARBAZINE; DNA; DRUG DERIVATIVE; HERMES ANTIGEN; NUCLEAR PROTEIN; PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BINDING; GENE DOSAGE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; DRUG ANTAGONISM; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CELL LINE, TUMOR; DACARBAZINE; DNA; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; PROTEINS;

EID: 33644822862     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.9405     Document Type: Article

References (56)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
2. Grossman SA, Batara JF: Current management of glioblastoma multiforme. Semin Oncol 31:635-644, 2004
3. Bredel M, Zentner J: Brain-tumour drug resistance: The bare essentials. Lancet Oncol 3:397-406, 2002
4. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
5. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
6. Bredel M, Bredel C, Sikic BI: Genomics-based hypothesis generation: A novel approach to unravelling drug resistance in brain tumours? Lancet Oncol 5:89-100, 2004
7. Bocangel DB, Finkelstein S, Schold SC, et al: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8:2725-2734, 2002
8. Kaina B, Christmann M: DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40:354-367, 2002
9. Karran P: Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22:1931-1937, 2001
10. Wang CY, Cusack JC Jr, Liu R, et al: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5:412-117, 1999
11. Nakanishi C, Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309, 2005
12. Weaver KD, Yeyeodu S, Cusack JC Jr, et al: Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187-196, 2003
13. Asch AS, Leung LL, Shapiro J, et al: Human brain glial cells synthesize thrombospondin. Proc Natl Acad Sci U S A 83:2904-2908, 1986
14. Scheck AC, Mehta BM, Beikman MK, et al: BCNU-resistant human glioma cells with overrepresentation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes. Genes Chromosomes Cancer 8:137-148, 1993
15. Norman SA, Rhodes SN, Treasurywala S, et al: Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display. Cancer 89:850-862, 2000
16. Kleihues P, Louis DN, Scheithauer BW, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-229, 2002
17. Stears RL, Getts RC, Gullans SR: A novel, sensitive detection system for high-density microarrays using dendrimer technology. Physiol Genomics 3:93-99, 2000
18. Pollack JR, Perou CM, Alizadeh AA, et al: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41-46, 1999
19. Pollack JR, Sorlie T, Perou CM, et al: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 99:12963-12968, 2002
20. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868, 1998
21. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121, 2001
22. Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100:9440-9445, 2003
23. Ikaha R, Gentleman RR: A language for data analysis and graphics. J Comp Graph Stat 5:299-314 1996
24. Wertz IE, O'Rourke KM, Zhou H, et al: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:694-699, 2004
25. Friedman JB, Brunschwig EB, Platzer P, et al: C8orf4 is a transforming growth factor B induced transcript downregulated in metastatic colon cancer. Int J Cancer 111:72-75, 2004
26. Nakashima K, Yanagisawa M, Arakawa H, et al: Astrocyte differentiation mediated by LIF in cooperation with BMP2. FEBS Lett 457:43-46, 1999
27. Hur GM, Lewis J, Yang Q, et al: The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. Genes Dev 17:873-882, 2003
28. Heyninck K, Kreike MM, Beyaert R: Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett 536:135-140, 2003
29. Bonni A, Sun Y, Nadal-Vicens M, et al: Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278:477-483, 1997
30. Koblar SA, Turnley AM, Classon BJ, et al: Neural precursor differentiation into astrocytes requires signaling through the leukemia inhibitory factor receptor. Proc Natl Acad Sci U S A 95:3178-8311, 1998
31. Kasza A, Rogowski K, Kilarski W, et al: Differential effects of oncostatin M and leukaemia inhibitory factor expression in astrocytoma cells. Biochem J 355:307-314, 2001
32. Halfter H, Kremerskothen J, Weber J, et al: Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor. J Neurooncol 39:1-18, 1998
33. Bruggink F, Hayes S: Identification of DNA binding proteins using the NoShift Transcription Factor Asssay Kit. Nat Methods 1:177-179, 2004
34. Pommier Y, Sordet O, Antony S, et al: Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 23:2934-2949, 2004
35. Opipari AW Jr, Boguski MS, Dixit VM: The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 265:14705-14708, 1990
36. Lee EG, Boone DL, Chai S, et al: Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289:2350-2354, 2000
37. Makarova KS, Aravind L, Koonin EV: A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. Trends Biochem Sci 25:50-52, 2000
38. Boone DL, Turer EE, Lee EG, et al: The ubiquitin-modifying enzyme A20 is required for termination of toll-like receptor responses. Nat Immunol 5:1052-1060, 2004
39. Robe PA, Bentires-Alj M, Bonif M, et al: In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10:5595-5603, 2004
40. Tran NL, McDonough WS, Savitch BA, et al: The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 280:3483-3492 2005
41. Inki P, Joensuu H, Grenman R, et al: Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70:319-323, 1994
42. Pulkkinen JO, Penttinen M, Jalkanen M, et al: Syndecan-1: A new prognostic marker in laryngeal cancer. Acta Otolaryngol 117:312-315, 1997
43. Nackaerts K, Verbeken E, Deneffe G, et al: Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer 74:335-345, 1997
44. Shah L, Walter KL, Borczuk AC, et al: Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101:1632-1638, 2004
45. Matsumoto A, Ono M, Fujimoto Y, et al: Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74:482-491, 1997
46. Wiksten JP, Lundin J, Nordling S, et al: Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95:1-6, 2001
47. Nemeth Z, Szigeti K, Mathe M, et al: Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: A prospective, randomized, clinicopathologic and immunohistochemical study. J Craniofac Surg 16:205-212, 2005
48. Diaz LK, Zhou X, Wright ET, et al: CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309-3314, 2005
49. Sillanpaa S, Anttila MA, Voutilainen K, et al: CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res 9:5318-5324, 2003
50. Wei JS, Greer BT, Westermann F, et al: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 64:6883-6891, 2004
51. Bendardaf R, Lamlum H, Ristamaki R, et al: CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer. Oncol Rep 11:41-45, 2004
52. Bodine SC, Latres E, Baumhueter S, et al: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704-1708, 2001
53. Cardozo T, Pagano M: The SCF ubiquitin ligase: Insights into a molecular machine. Nat Rev Mol Cell Biol 5:739-751, 2004
54. Jin J, Cardozo T, Lovering RC, et al: Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18:2573-2580, 2004
55. Gotoh M, Sato T, Kiyohara K, et al: Molecular cloning and characterization of beta1,4-N-acetylgalactosaminyltransferases IV synthesizing N,N′-diacetyllactosediamine. FEBS Lett 562:134-140, 2004
56. Chou TY, Hart GW: O-linked N-acetylglucosamine and cancer: Messages from the glycosylation of c-Myc. Adv Exp Med Biol 491:413-418, 2001